PharmaMar’s lurbinectedin granted orphan drug designation by FDA for small cell lung cancer treatment
Spanish pharmaceutical company PharmaMar has announced that its cancer drug, lurbinectedin, has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC). This designation marks a critical milestone in the development of lurbinectedin, highlighting its potential in treating this aggressive form of cancer. Lurbinectedin […]